Peng Zhao

Dr. Peng Zhao

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 May 2023 in ACS Nano
Verified
Journal Article
Closed access
THTingting He
Tingting He
LWLu Wang
Lu Wang
SGShuangquan Gou
Shuangquan Gou
LLLu Lu
Lu Lu
GLGenhua Liu
Genhua Liu
KCKaiyong Cai
Kaiyong Cai

20 August 2021 in Science Advances
Verified
Journal Article
Open access
PZPeng Zhao
Peng Zhao
QYQingzhou Yao
Qingzhou Yao
PZPei-Jian Zhang
Pei-Jian Zhang
ETErlinda The
Erlinda The
YZYufeng Zhai
Yufeng Zhai
XMXianzhong Meng
Xianzhong Meng
Shear stress induces endothelial transition to pro-inflammatory mesenchymal phenotype in a coronary artery–on–a–chip model.

1 June 2024 in Bioactive Materials
Verified
Journal Article
Open access
WGWenbo Geng
Wenbo Geng
JZJie Zhao
Jie Zhao
BTBailong Tao
Bailong Tao
YYYulu Yang
Yulu Yang
QDQiaojian Duan
Qiaojian Duan
KCKaiyong Cai
Kaiyong Cai
The rheumatoid arthritis (RA) microenvironment is often followed by a vicious circle of high inflammation, endogenous gas levels imbalance, and poor treatment. To break the circle, we develop a dual-gas-mediated injectable hydrogel for modulating the immune microenvironment of RA and simultaneously releasing therapeutic drugs. The hydrogel (DNRS gel) could be broken down on-demand by consuming excessive nitric oxide (NO) and releasing therapeutic hydrogen sulfide (H2S), resulting in endogenous gas restoration, inflammation alleviation, and macrophage polarization to M2 type. Additionally, the hydrogel could suppress osteoclastogenesis and enhance osteogenesis. Furthermore, the intra-articularly injected hydrogel with methotrexate (MTX/DNRS gel) significantly alleviated inflammation and clinical symptoms and promoted the repair of bone erosion in the collagen-induced arthritis rat model. As a result, in vivo results demonstrated that MTX/DNRS gel restored the microenvironment and improved the therapeutic effect of MTX. This study provides a novel understanding of developing versatile smart delivery platforms for RA treatment.

1 July 2025 in Bioactive Materials
Verified
Journal Article
Open access
XXXinzhi Xu
Xinzhi Xu
HZHang Zhou
Hang Zhou
RHRuixia Hong
Ruixia Hong
JGJiaqi Gong
Jiaqi Gong
YWYujie Wan
Yujie Wan
FLFang Li
Fang Li
Triple-negative breast cancer (TNBC) presents therapeutic challenges due to its aggressive, drug-resistance, and low immunological reactivity. Cuproptosis, an emerging therapeutic modality, is a promising strategic intervention for treating TNBC. Nonetheless, the effectiveness of cuproptosis is compromised by tumor adaptations, including the Warburg effect, increased intracellular glutathione (GSH), and copper efflux, thus breaking the barrier of cuproptosis is the basis for developing cuproptosis-based clinical therapies. Herein, a self-accelerating strategy utilizing a pH-responsive copper framework encapsulating glucose oxidase (GOx), modified with polyethylene glycol (PEG) and tumor-penetrating peptide (tLyp1) has been developed. Upon reaching the acidic tumor microenvironment, the released GOx increases intracellular acidity and hydrogen peroxide (H2O2). The elevated intracellular GSH and H2O2 serve as “fuel” to amplify the copper-based catalytic within tumor cells. Concurrently, the reduction of copper efflux proteins (ATP7B) and the depletion of GSH lead to copper overload in tumor cells, leading to cuproptosis via copper overload, mitochondrial disruption, and Fe-S protein instability. This constellation of interrelated events constitutes a potent “Copper Bomb,” which concurrently triggers the immune system and effectively kills the tumor. It robustly engages innate and adaptive immunity via the release of mitochondrial DNA, facilitating the cGAS-STING pathway and precipitating immunogenic cell death. This process reverses the immunosuppressive tumor microenvironment, eliminates tumor cells, and suppresses metastasis, thus offering a novel therapeutic modality for the comprehensive treatment of triple-negative breast cancer (TNBC).

1 September 2025 in Bioactive Materials
Verified
Journal Article
Open access
YWYi Wang
Yi Wang
XLXuemei Liao
Xuemei Liao
QGQinglong Guo
Qinglong Guo
HZHeng Zhang
Heng Zhang
LYLei Ye
Lei Ye
HCHongwei Cheng
Hongwei Cheng
Parkinson's disease (PD), a progressive neurodegenerative disorder, is marked by the degeneration of dopaminergic neurons. Emerging evidence highlights the critical involvement of neuronal ferroptosis and microglial pyroptosis in PD pathogenesis. In this study, we first characterized systemic inflammatory alterations in the peripheral blood of PD patients compared to healthy controls, revealing distinct pro-inflammatory signatures. Based on these findings, we engineered BV2 microglial membrane-camouflaged biomimetic multienzyme gallic acid-selenium nanoparticles (BM@GA-Se nanosomes) and evaluated their neuroprotective potential. In vitro and in vivo experiments demonstrated that BM@GA-Se nanosomes enhanced neuronal survival by simultaneously suppressing ferroptosis of neurons (via GPX4-mediated lipid peroxide reduction) and pyroptosis of microglia (through inhibition of the HSP90/NLRP3/Caspase-1 signaling pathway). These results position BM@GA-Se nanosome as a new dual-pathway targeting therapeutic strategy, offering a promising translational approach to mitigate PD progression by addressing interdependent inflammatory and oxidative mechanisms.

20 May 2025 in Advanced Healthcare Materials
Verified
Journal Article
Closed access
BZBeige Zong
Beige Zong
YLYongquan Lu
Yongquan Lu
ZLZhongfu Li
Zhongfu Li
LPLian Pan
Lian Pan
PZPeng Zhao
Peng Zhao
KCKaiyong Cai
Kaiyong Cai